An2 Therapeutics (ANTX)CFO sold ~$3.3K

~$3.3K

Approx. value · 3,295 sh @ $1.00

81K

Holds after · shares reported

Traded

Jan 5, 2026

Filed

Jan 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 4, 2025Insider · 2 peopleInsiders: 2 sales (~$4K)
2. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
3. Jan 5, 2026 · this disclosureInsiderCFO sold ~$3.3K of ANTX shares in the open market

What came next

1. Jan 5, 2026Insider · 3 peopleInsiders: 3 sales (~$25K)
2. Jan 6, 2026Insider · 4 peopleInsiders: 4 sales (~$22K)
3. Jan 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 26, 2026, the Board of Directors (the “Board”) of AN2 Therapeutics, Inc. (the “Company”) appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer of the Company.”
4. Mar 3, 2026InsiderOfficer sold ~$347 of ANTX shares in the open market
5. Mar 8, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
6. Mar 17, 2026Company filing · Form 8-K · ResultsReported its results
7. Mar 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 19, 2026 (the “Repricing Date”), in accordance with the AN2 Therapeutics, Inc. Amended and Restated 2017 Equity Incentive Plan (the “2017 Plan”) and the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (together with the 2017 Plan, the “Plans”), the Board of Directors (the “Board”) of AN2 Therapeutics, Inc. (the “Company”) approved a stock option repricing (the “Option Repricing”), effective as of the…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for An2 Therapeutics

For An2 Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANTX page.

Other recent filings by Lucy Day, Chief Financial Officer

• SEC Form 4 at An2 Therapeutics (ANTX)Jan 8, 2026
• SEC Form 4 at An2 Therapeutics (ANTX)Jan 8, 2025

The full history of Lucy Day, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at An2 Therapeutics

• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026
• SEC Form 4Sep 8, 2026

Everything OQRO holds on this company is on its ANTX page.